
| 2019 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| 2016 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2012 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2019 | 0 | 14.534.366 | 464.195 | 1 | ||
| 2016 | 0 | 7.113.779 | 888.685 | 1 | ||
| 2012 | 0 | 5.998.134 | 611.689 | 1 | ||
Total number of partners: 45
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 45
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2019-04-01 | SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH. | SAFE-N-MEDTECH | participant | 14.534.366 | 28 |
| 2016-04-01 | Nanomedicine upscaling for early clinical phases of multimodal cancer therapy | NoCanTher | participant | 7.113.779 | 12 |
| 2012-03-01 | DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma | DARTRIX | participant | 5.998.134 | 8 |